Immunotherapies for Staphylococcus aureus: Current challenges and future prospects

Infection Control and Hospital Epidemiology

Volumn 31, Issue SUPPL. 1, 2010, Pages

  Deresinski, Stan ^a   Herrera, Victor ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTASTAPH; AUROGRAB; ETI 2211; IMMUNOGLOBULIN; PAGIBAXIMAB; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; VANCOMYCIN; VERONATE;

BACTEREMIA; BACTERIAL COLONIZATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; WOUND INFECTION;

BACTERIAL VACCINES; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 78449239405     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/655992     Document Type: Conference Paper

References (10)

1. Zetola N, Francis J, Nuermberger E, Bishai W. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5(5):275-286. (Pubitemid 40602247)
2. Lucero CA, Hageman J, Zell ER, et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population- based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine 2009;27(37):5061-5068.
3. Nabi Biopharmaceuticals. Nabi Biopharmaceuticals announces results of StaphVAX® confirmatory phase III clinical trial. News release. November 1, 2005. http://www.nabi.com/. Accessed April 12, 2010.
4. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346(7):491-496.
5. Becher D, Hempel K, Sievers S, et al. A proteomic view of an important human pathogen - towards the quantification of the entire Staphylococcus aureus proteome. PLoS One 2009;4(12):e8176.
6. Ziebandt AK, Kusch H, Degner M, et al. Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. Proteomics 2010;10(8):1634-1644.
7. Yoong P, Pier G. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A 2010;107(5):2241-2246.
8. ClinicalTrials.gov. An evaluation of three dose levels of 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Sponsor: Wyeth. ClinicalTrials.gov identifier NCT01018641. http://www.clinicaltrials.gov/. Accessed April 12, 2010.
9. Kim HK, Dedent A, Cheng AG, et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010;28(38):6382-6392.
10. Stranger-Jones Y, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 2006;103(45):16942- 16947. (Pubitemid 44737357)